Xellia at-a-glance

Specialty pharmaceutical company focused on critical care therapies for life-threatening diseases, supplying both APIs and FDFs.

 

B2B sales to approx. 500 customers in 70 countries.

 

50+ years expertise in supplying fermented and semi-synthetic products that are challenging to manufacture.

 

State-of-the-art production facilities in the United States, Europe and Asia with global regulatory approval and an unsurpassed compliance track record.

 

Continuously expanding product pipeline and geographic reach.

 

Wholly owned by Novo Holdings A/S and well financed with growing sales.

2018: Revenue at 316 MUSD  where the product portfolio split is represented by 41% API and
59% FDF